NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) major shareholder Pharma (Hong Kong) Co Pioneer sold 24,326 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $4.04, for a total transaction of $98,277.04. Following the completion of the transaction, the insider now owns 5,188,421 shares of the company’s stock, valued at $20,961,220.84. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
NYSEAMERICAN NBY traded down $0.39 on Friday, hitting $1.68. 295,586 shares of the stock were exchanged, compared to its average volume of 1,268,729. NovaBay Pharmaceuticals, Inc. has a 52-week low of $0.23 and a 52-week high of $4.04.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The firm had revenue of $1.49 million during the quarter.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Featured Story: How do taxes affect a CDs total return?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.